Structural basis of Mos1 transposase inhibition by the anti-retroviral drug Raltegravir.
Structural basis of Mos1 transposase inhibition by the anti-retroviral drug Raltegravir.
复制标题
DOI:
10.1021/cb400791u
复制
发表时间:
2014-03-21
影响因子:
4
通讯作者:
Richardson, Julia M.
中科院分区:
文献类型:
--
作者:
Wolkowicz, Urszula M.;Morris, Elizabeth R.;Robson, Michael;Trubitsyna, Maryia;Richardson, Julia M.
DNA transposases catalyze the movement of transposons around genomes by a cut-and-paste mechanism related to retroviral integration. Transposases and retroviral integrases share a common RNaseH-like domain with a catalytic DDE/D triad that coordinates the divalent cations required for DNA cleavage and integration. The anti-retroviral drugs Raltegravir and Elvitegravir inhibit integrases by displacing viral DNA ends from the catalytic metal ions. We demonstrate that Raltegravir, but not Elvitegravir, binds to Mos1 transposase in the presence of Mg2+ or Mn2+, without the requirement for transposon DNA, and inhibits transposon cleavage and DNA integration in biochemical assays. Crystal structures at 1.7 Å resolution show Raltegravir, in common with integrases, coordinating two Mg2+ or Mn2+ ions in the Mos1 active site. However, in the absence of transposon ends, the drug adopts an unusual, compact binding mode distinct from that observed in the active site of the prototype foamy virus integrase.
登录
查看更多内容
影响因子:
5.6
作者:
Perryman AL;Forli S;Morris GM;Burt C;Cheng Y;Palmer MJ;Whitby K;McCammon JA;Phillips C;Olson AJ
通讯作者:
Olson AJ
影响因子:
5.8
作者:
Gouet, P;Courcelle, E;Métoz, F
通讯作者:
Métoz, F
影响因子:
16
作者:
Dawson, A;Finnegan, DJ
通讯作者:
Finnegan, DJ
影响因子:
64.8
作者:
通讯作者:
--
DOI:
10.1111/j.1749-6632.2011.05972.x
发表时间:
2011-01-01
期刊:
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION
影响因子:
--
作者:
Nguyen, Bach-Yen T.;Isaacs, Robin D.;Hazuda, Daria J.
通讯作者:
Hazuda, Daria J.